Skip to main content
CARMAT logo

CARMAT — Investor Relations & Filings

Ticker · ALCAR ISIN · FR0010907956 LEI · 969500ARXACM0P0KH333 PA Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2021-02-26 Capital/Financing Update
Country FR France
Listing PA ALCAR

About CARMAT

https://www.carmatsa.com/en/

CARMAT is a medical technology company that designs, develops, and markets the Aeson® total artificial heart. This bioprosthetic device provides a therapeutic solution for patients suffering from end-stage biventricular heart failure. Aeson® is designed to replace the native heart, primarily as a bridge to transplantation for eligible patients. A key feature of the device is its self-regulation capability, which uses embedded sensors and biocompatible materials to automatically adapt blood flow based on the patient's physiological needs, thereby mimicking the function of a natural heart.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Capital/Financing Update Classification · 1% confidence The document is explicitly titled as a "PRESS RELEASE" and details the launch of a significant financial transaction: a capital increase (equity fundraising) of €50 million, potentially up to €57.5 million, involving a priority subscription period for existing shareholders and a global offering. This directly relates to the company's financing activities and capital structure changes. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it describes a specific corporate action related to capital raising.
2021-02-26 English
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 1% confidence The document is a press release titled "CARMAT lance une augmentation de capital avec suppression du droit préférentiel de souscription des actionnaires..." (CARMAT launches a capital increase with suppression of the pre-emptive subscription right of shareholders...). The text details the launch of a capital increase operation, specifying the amount (€50 M to €57.5 M), the mechanism (offering to the public and global placement), the priority period for existing shareholders, and the intended use of the funds (production ramp-up, clinical trials). This content directly relates to fundraising, financing activities, and capital structure changes. Based on the definitions, this clearly falls under 'Capital/Financing Update' (Code: CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it is the primary document detailing the financing event itself.
2021-02-26 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and its primary purpose is to announce the "Availability of the 2020 Universal registration document." It states that the document was filed with the French stock-market authority (AMF) and is now available to the public and on the company website. The text mentions that the Universal Registration Document includes the annual financial report, corporate governance report, and auditors' reports, but the document provided here is the announcement *about* the availability of that larger filing, not the filing itself. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report has been published or is available points towards a Report Publication Announcement (RPA). Since this is a formal announcement regarding the publication of a major regulatory filing (Universal Registration Document), RPA is the most appropriate classification.
2021-02-25 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is explicitly titled "Mise à disposition du Document d'enregistrement universel 2020" (Making available of the 2020 Universal Registration Document). It states that the document, which integrates the annual financial report, corporate governance report, and auditor reports for the year ended December 31, 2020, has been filed with the AMF (Autorité des Marchés Financiers) and is made available to the public. This is a press release announcing the availability of a comprehensive annual filing. Since the text is an announcement about the availability of the full annual report (which would typically be a 10-K or equivalent comprehensive annual filing), and it is a short press release format, it best fits the 'Report Publication Announcement' (RPA) category, as per Rule 2 (Menu vs Meal Rule). While the content *describes* what is in the annual report, the document itself is the announcement of its publication.
2021-02-25 French
Carmat - DEU 2020
Annual Report Classification · 1% confidence The document is a 'Document d'Enregistrement Universel' (Universal Registration Document) for the year 2020, which includes the Annual Financial Report. In the context of French corporate filings, this is the equivalent of an Annual Report (10-K). It contains comprehensive information including management reports, financial statements, audit reports, and governance details. It is not a mere announcement (RPA) as it contains the full substantive content of the annual reporting package. FY 2020
2021-02-24 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces a specific operational update: CARMAT receiving FDA approval to use a new version of its artificial heart in the US Early Feasibility Study (EFS), with enrollment expected in Q1 2021. This is a time-sensitive, material announcement intended for immediate public dissemination, characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change (MANG), it fits best as an Earnings Release (ER) as it provides key operational and progress updates often bundled with financial reporting periods, or RNS as a general regulatory update. Given the nature of the update (FDA approval/study progress), it functions as a key operational highlight release, making ER the slightly better fit than the generic RNS, although RNS is also plausible. However, since it is a press release detailing operational progress rather than just announcing the *release* of a report (RPA), ER is chosen as the primary category for significant operational news.
2021-02-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.